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SUMMARY AT A GLANCE
Treatment of steroid-dependent frequent re-
lapsing nephrotic syndrome is challenging is-
sue. The manuscript examining the efﬁcacy
and safety of treatment of rituximab for those
patinets give us meaning information in the
ﬁeld of clinical nephrology.
ABSTRACT:
Aim: Treatment of frequently relapsing or steroid-dependent minimal change
disease (MCD) in children and adults remains challenging. Glucocorticoids
and/or other immunosuppressive agents are the mainstay of treatment, but
patients often experience toxicity from prolonged exposure and may either
become treatmentdependent and/or resistant. Increasing evidence suggests that
rituximab (RTX) canbeauseful alternative to standard immunosuppression and
allowwithdrawal of maintenance immunosuppressants; however, data on opti-
mal treatment regimens, long-term efﬁcacy and safety are still limited.
Methods: Weundertookaprospective studyofRTXtoallow immunosuppression
minimization in 15 young adults with frequently relapsing or steroid-dependent,
biopsy-proven MCD. All patients were in remission at the start of treatment and
on a calcineurin inhibitor. Two doses of RTX (1gr) were given 6months apart. A
subset of patients also received an additional dose 12months later, in order to
examine the beneﬁt of re-treatment. Biochemical and clinical parameters were
monitored over an extended follow-up period of up to 43months.
Results: Median steroid-free survival after RTX was 25months (range 4–34).
Mean relapse frequency decreased from 2.60±0.28 to 0.4±0.19 (P< 0.001) after
RTX. Seven relapses occurred, ﬁve of which (71%) when CD19 counts were
greater than 100μ. Immunoglobulin levels remained unchanged, and nomajor
side effects were observed throughout the follow-up period.
Conclusions: Rituximab therapy is effective at maintaining prolonged steroid-
free remission and reducing relapse frequency in this group of patients. Our
study lends further support for the role of RTX in the treatment of patients
with frequently relapsing or steroid-dependent MCD.
Minimal change disease (MCD) is the most common cause of
nephrotic syndrome (NS) in children and accounts for up to
20%ofNS in adults 1. The disease derives its name from the nor-
mal (minimal change) appearance of glomeruli on light and
immunoﬂuorescence microscopy due to lack of immunoglobu-
lin or complement deposition. Electron microscopy, however,
reveals the loss of the highly branched podocyte morphology
with widespread effacement of foot processes. Although the
exact aetiology of MCD remains unknown, dysregulation of
the immune system is thought to be an important factor in its
pathogenesis 2.
Steroids are themainstay of treatment forMCD, and approx-
imately, 80% of patients will respond to an initial course of
prednisolone. However, relapse rates are high, especially in
younger patients (<40 years old) 3, and between 56% and
76% of patients will experience at least one relapse with
tapering or withdrawal of the initial steroid therapy.
Relapses are also seen in 40% of adults who hadMCD during
childhood 3–5. Repeated courses of steroids are needed for
recurrent relapses with signiﬁcant resultant morbidity and
mortality 6,7. Frequent relapses and hospital visits also
impact adversely on work, education and overall quality of
life 8,9. Immunosuppressive (IS) agents, such as calcineurin
inhibitors (CNIs) (cyclosporine A /tacrolimus), cyclophos-
phamide and mycophenolate mofetil, are often used in an
attempt to reduce relapse frequency and therefore avoid
the severe adverse side effects of steroid treatment. How-
ever, prolonged use of CNI can result in side effects including
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nephrotoxicity, hirsuitism, hypertension and hyperlipidae-
mia 10,11. Moreover, at least 30% of patients continue to suf-
fer frequent relapses despite repeated courses of the
aforementioned therapies and can remain steroid depen-
dent with relapses of NS following discontinuation of
steroids, or during the tapering phase of treatment 3. These
patients have increased risk of complications because of the
use of repeated courses of steroids and other IS agents (in
many cases for >15–20 years) and are therefore in urgent
need of a more effective and safe treatment.
Rituximab (RTX) is a chimeric monoclonal antibody
inhibiting CD-20 mediated B-cell proliferation and differ-
entiation, successfully used in non-Hodgkin lymphoma,
systemic diseases such as rheumatoid arthritis or severe
anti-neutrophil cytoplasmic antibody-associated vasculitis
and renal disorders such as membranous nephropathy
12,13. In children, RTX has been used since 2006 to treat fre-
quently relapsing NS and, in 2012, was included in the Kid-
ney Disease: Improving Global Outcomes Guidelines for the
Treatment of Glomerulonephritis in Children, as an option for
the treatment of this challenging group of patients 14. In
adults, increasing evidence suggests that RTX is capable of
reducing relapse frequency and concomitant immunosup-
pression in 65–85% of patients 15–19. However, its use has
been very varied: different dosage regimes, in mixed popu-
lations (steroid dependent and/or steroid resistant) and for
differing indications (induction or maintenance of remis-
sion). As a result, it is still not clear whether RTX is best used
to induce remission or to maintain it, what the optimal dose
should be and whether repeated doses improve response
rates and prolong remission. Additional data are therefore
needed to inform clinical practice on how best to use RTX
in this patient population, so that deﬁnitive randomized
trials can be planned. The aim of this study was to evaluate
the efﬁcacy and safety of a standard dose of RTX in main-
taining remission, reducing relapse frequency and with-
drawing immunosuppression, in a group of adult patients
with frequently relapsing and steroid-dependent MCD.
METHODS
Patient population and follow up
Fifteen adult patients (18–46years old), nine male and six
female, fulﬁlling the following criteriawere enrolled in this study:
1 Biopsy-proven MCD
2 Frequently relapsing or steroid-dependent disease. Frequent
relapse was deﬁned as two or more relapses within 1year.
Steroid dependence was deﬁned as relapse upon tapering
steroid therapy or within 4weeks of discontinuing steroids
and need for long-term maintenance steroids
3 Maintenance immunosuppression with a CNI (cyclosporine
A or tacrolimus)
4 Remission of NS deﬁned as proteinuria <3.5 g/day
5 No previous RTX treatment
We enrolled patients consecutively from December 2011
until July 2014 when funding for RTX, for this indication,
was restricted in the UK. Clinical and laboratory data were
obtained at baseline, 6, 12, 18months and every 6months after
that until 36months. Laboratory data included serum albumin
levels, urine protein/creatinine ratio, immunoglobulin levels
and CD19 cell counts. Follow-up period for the group as a
whole was 12–43months (median 20) and concluded in July
2015. The study conformed to the ethical standards of the
Declaration of Helsinki, and all subjects gave informed consent
prior to inclusion in the study.
Treatment
The protocol for RTX administration is shown in Figure 1. A
standard dose of 1 gr was used for all patients. Twelve patients
received two doses at an interval of 6months (T0 and T6).
Three patients received only a single dose because of funding
restrictions. Four patients received an additional RTX dose, at
18months in order to evaluate the safety and efﬁcacy of re-
treatment (T18). Where appropriate, data for these groups are
presented separately.
Fig. 1 Schematic representation of the treatment protocol. All patients at T0 were given 1 gr rituximab (RTX). Steroids were tapered and withdrawn within 3months
(T3) if applicable. A second RTX dose was given 6months later (T6). At 1 year (T12), calcineurin inhibitor (CNI) was reduced by 25% if no relapses had occurred. Four
patients received an additional RTX dose 18months after the ﬁrst dose (T18).
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In order to minimize infusion reactions, 40mg methylpred-
nisolone, 10mg Piriton and 1 gr Paracetamol were adminis-
tered prior each RTX infusion. B-cell depletion, deﬁned as a
peripheral blood CD19 cell count of<5 cells/μl, was conﬁrmed
2weeks post-treatment and at every follow-up visit (normal
range in our laboratory deﬁned as 100–500 cells/μl). Patients
who did not deplete their B cells were re-treated 4weeks later.
If patients were on concomitant steroids, they were tapered
and withdrawn by 3months following the ﬁrst RTX dose. At
12months, if no relapse had occurred, CNI dose was reduced
by 25%. Following the initial reduction, CNI dose was reduced
by 25% at six monthly intervals. NS relapse was treated as per
standard protocol in our unit with 1mg/kg prednisolone (max
60mg/day) until remission, followed by gradual weaning over
8–12 weeks and reinstatement of the original CNI dose. No
change in other medications (ACE inhibitors or ARBs) was
introduced throughout the study period.
Statistical analysis
Data are expressed as mean±SEM, medians and percentages
as appropriate. The Kaplan–Meier method was used to plot
the steroid-free remission time, determined from the time ste-
roids were withdrawn until the ﬁrst relapse. Patients not
having a relapse until the end of the follow-up period were
considered as censored at the time of the last visit. All statistical
analysis was performed using PRISM 6 software. Statistical
signiﬁcance was established at P<0.05.
RESULTS
Patient characteristics
The baseline characteristics of all the patients are summarized
in Table 1.
Sixty per cent of patients were Caucasian men with disease
onset at <18years of age. The median age of disease onset was
5years (1–38) and the median age at treatment was 27years
(range 18–46). All patients had previously received long-term cor-
ticosteroid therapy and at least one IS drug such as CNI (n=10),
MMF (n=3), levamisole (n=3), cyclophosphamide (n=5). All
patients were in remission (mean albumin 41.4±1.3mg/dl and
urine protein/creatinine ratio 43±23.7) and on a CNI at the time
of RTX treatment. Twelve patients were on maintenance steroids
(mean dose 8±1.85mg; range 0–20mg), which were tapered by
3months following RTX treatment. B-cell depletion was not
achieved in two patients: the ﬁrst one was not re-treated and
relapsed 4months later, prior to their second RTX dose, and the
second was re-dosed at 4weeks.
Steroid-free remission and relapses
Median time of steroid-free remission was 25months (range
4–34) for the group as a whole (Fig. 2). Looking at the groups
separately based on RTX dosing (Table 2), patients that
received two doses of RTX 6months apart (n=8) remained
in steroid-free remission after a median follow-up period of
17months (range 4–31); patients that received one dose of
RTX (n=3) remained in steroid-free remission after a median
follow-up period of 12months (range 12–16). Patients that
received an additional RTX dose at 18months (n=4) remained
in steroid-free remission for a median follow-up period of
27months (range 25–30).
Table 1 Baseline patient characteristics
Overall cohort
(n = 15)
Demographics
Age at treatment (yr) 27 (18–45)
Male sex 9 (60%)
Caucasian 9 (60%)
Disease characteristics
<18 years at onset 9 (60%)
Duration of disease (years) 17 (2–27)
Steroid-dependent/frequently relapsing nephrotic syndrome 8/7
Previous immunosuppression
Oral steroids 15 (100%)
Calcineurin inhibitors
Cyclosporine 6 (60%)
Tacrolimus 4 (40%)
Antiproliferative or cytotoxic agents
Cyclophosphamide 5 (50%)
Mycophenolate mofetil 3 (30%)
Levamisole 3 (20%)
Clinical parameters
Albumin (mg/dl) 41.4 ± 1.3
Urine protein/creatinine ratio 43 ± 23.7
Creatinine mmol/l 84.4 ± 21.12
Data are presented as median and range or if continuous as mean ± SEM. Cate-
gorical data are expressed as numbers and percentages.
Fig. 2 Rituximab achieves prolonged steroid-free remission. Kaplan–Meier
curve showing the percentage of patients in steroid-free remission after
rituximab therapy. Median steroid-free remission for the group as a whole was
25months.
Rituximab for minimal change disease
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Overall, 39 relapses occurred in this group of patients in the
year prior to RTX treatment compared with seven during the
entire follow-up period post-RTX. Relapse frequency (number
per patient per year) decreased from 2.60±0.28, in the year prior
to RTX treatment, to 0.46±0.19 (P< 0.001) post-treatment
(Fig. 3A,B). One relapse occurred early on in the study period
(4months post-steroid withdrawal; 6months post-RTX treat-
ment) in a patient who did not completely deplete their CD19
count following the ﬁrst RTX dose. Following the second RTX
dose, which achieved CD19 depletion, the patient had a
10-month steroid-free remission period before the occurrence of
another relapse. Another relapse occurred 19months post-steroid
withdrawal in a patient who had stopped his CNI (tacrolimus).
B-cell counts and concurrent medication
A single dose of 1 gr RTX successfully depleted CD19 lympho-
cytes in 86% (n=13/15) of patients. CD19 cells progressively
re-emerged in the circulation 6–12months following each
RTX infusion (Fig. 4A). Most relapses (ﬁve out of seven)
occurred with CD19 counts of 100 cells/μl or greater (Fig. 4B).
Two relapses occurred below this level, in the same patient;
the ﬁrst at a CD19 count of 66 cells/μl and the subsequent
one at 99cells/μl. In the patients that relapsed, average CD19
count at the time of relapse was 351±166 cells/μl.
Steroids were discontinued in all patients within 3months of
the ﬁrst RTX infusion and were not restarted unless for the treat-
ment of a relapse. Tacrolimus (Fig. 5A) and cyclosporine A
(Fig. 5B) average daily dose was compared over a period of
24months pre-RTX and post-RTX. At the 12month time point,
average tacrolimus dose was reduced from 6.75±1.236 to 4.50
±1.118mg/day (P=0.08), and a similar reduction was observed
for cyclosporine A (206±20 vs 155.83±19.5mg/day, P=0.08).
Adverse events
No serious adverse events were observed during the entire
follow-up period. One episode of lower respiratory tract
infection and one episode of gastroenteritis were reported
in the 3months following RTX treatment. Seven patients
(46%) experienced Type I hypersensitivity reactions during
RTX administration. Repeated RTX administration has been
reported to reduce immunoglobulin levels 20, but we did
not observe any signiﬁcant differences in the group overall
(Fig. 6A) or in the four patients who received three doses
of RTX (Fig. 6B). Average IgG levels at baseline were 6.77
± 0.637 g/dl and at 1 year 8.725 ± 1.068 g/dl.
DISCUSSION
Patients with frequently relapsing or steroid-dependent MCD
pose a signiﬁcant therapeutic challenge. In this prospective, obser-
vational study, we describe an effective treatment with RTX that
achieves prolonged steroid-free remission, reduces relapse fre-
quency and consequently exposure to glucocorticoids and CNI.
Table 2 Follow-up duration and time to ﬁrst relapse following rituximab
Patient
Rituximab total
exposure (mg)
Follow up
(months)
Time to ﬁrst relapse
(steroid free)
1 3000 43 25months‡
2 3000 37 no relapse
3 3000 33 25months
4 3000 31 no relapse
5 2000 31 19months
6 2000 30 no relapse
7 2000 27 no relapse
8 2000 20 no relapse
9 3000† 20 4 months‡
10 2000 17 no relapse
11 2000 17 no relapse
12 3000† 17 no relapse
13 1000 16 no relapse
14 1000 14 12months
15 1000 12 no relapse
†received additional rituximab after the ﬁrst dose as did not fully deplete CD19
count. ‡second relapse 10months later.
Fig. 3 Rituximab (RTX) reduces relapse frequency. (A) Relapse frequency (expressed as mean ± SEM) and distribution (B) in the year before RTX therapy (black bars)
and over the entire follow-up period after treatment (white bars).( ) Pre-RTX. ( ) Post-RTX.
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The rationale for the use of RTX in MCD comes from data
suggesting a potential role of B cells in the pathophysiology of
NS 21, data showing that RTX may have a beneﬁcial effect on
the podocyte cytoskeleton and the recovery of foot process
effacement 22,23 and from studies and case series showing that
RTX can induce remission of NS (for systematic review 24).
Fig. 4 Circulating CD19B cells following rituximab (RTX) therapy. (A) Circulating CD19 cells remained low (<100 cells/μl) in all patients for at least 6months after RTX but started
to reappear in the circulation 12months following the last RTX dose. Red lines indicate normal range in our laboratory 100–500 cells/μl. ( ) 1 dose. ( ) 2 doses. ( ) 3 doses.
(B) Majority of relapses (red symbols) occurred at a CD19 level greater than 100 cells/ml. ( ) Patient 1. ( ) Patient 2. ( ) Patient 3. ( ) Patient 4. ( ) Patient 5.
Fig. 5 Rituximab (RTX) reduces concurrent immunosuppression. Average daily dose of tacrolimus (A) and cyclosporine A (B) over 24months pre-RTX and post-RTX.
AUC, area under the curve.
Fig. 6 Immunoglobulin levels remain stable following RTX therapy. (A) Immunoglobulin levels were measured at different time points following RTX treatment and did
not show signiﬁcant variation from baseline. ( ) IgG counts. ( ) IgA counts. ( ) IgM counts. (B) IgG levels in patients receiving three doses RTX remained stable
throughout the observation period. ( ) Patient 1. ( ) Patient 2. ( ) Patient 3. ( ) Patient 4.
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However, as most data on RTX efﬁcacy are derived from retro-
spective studies, and the observation period in prospective
studies to date has been limited to 12months; data on its
long-term efﬁcacy and safety are lacking. To our knowledge,
our study is the only prospective studywith an extended obser-
vation period of up to 43months. Our results show that RTX
therapy can achieve prolonged steroid-free remission (median
time 25months) and signiﬁcantly reduce relapse frequency.
The importance of this result is ampliﬁed given the young age
of the patients and the signiﬁcant and well-documented toxic-
ity associated with prolonged steroid and CNI exposure.
Similar long-term efﬁcacy has been reported in several retro-
spective series 15–17,25. In the study by Guitard et al. (n=41
adults) median relapse-free time post-RTX was 18months
(range 3–36), although it is not clear if all patients included in
the analysis were off steroids. We did not stop concurrent CNI
therapy in our population but reduced it by 25% at 12months
and by 25% at 6month intervals thereafter in eligible patients,
which resulted in signiﬁcant dose reduction. This might have
contributed to the prolonged remission period observed as CNIs
have been reported to have an anti-proteinuric effect through
stabilization of the podocyte cytoskeleton 26. This strategy was
adopted at the time of study initiation as the efﬁcacy of RTX
monotherapy in this group of patients was less well studied,
and we deemed removal of all IS too high risk in this popula-
tion. Emerging evidence since then suggests that future trials
should address withdrawal of all IS medication following RTX.
As the aim of our study was to extend the period of
steroid-free remission in this group of patients, we used
RTX in remission. Whether RTX can be used only as a
steroid/IS-sparing agent or to induce remission without the
need for concomitant steroid therapy is an important ques-
tion that remains unanswered. Earlier studies suggested that
relapse rates were lower when RTX was given in remission 16
and that there may be increased urinary loss of RTX in
patients with nephrotic range proteinuria 27; the latter obser-
vation supported by the ﬁnding that RTX-treated patients
with idiopathic membranous nephropathy have lower
serum concentrations of RTX compared with patients with
rheumatoid arthritis 28. More recent studies however suggest
that RTX alone may be sufﬁcient to induce remission in adults
15,17. Further evidence from, ideally a randomized controlled
study, would be needed to clarify this important question.
We elected to use a standard dose of 1 gr for all patients as
this dose has been shown to reliably deplete CD19 counts 29
and is substantially more cost-effective and convenient for
patients than multiple dosing. An important observation from
our study is that in our cohort, relapses occurred in the main
upon reappearance of CD19 counts in the circulation above
the lower normal limit of 100 cells/μl with the average CD19
count at relapse being 410±23 cells/μl. Of interest is also the
observation that the one patient in our cohort that relapsed
early (within 6months of RTX) had not depleted their CD19
cells fully post-RTX. This patient also reconstituted their B cells
much faster than the rest of the cohort to a level >100 cells/μl
and relapsed each time. A similar association between B-cell
recovery and relapse has been reported in other studies. In a
Japanese cohort of 25 adult MCD patients, treated with a simi-
lar RTX protocol, no relapses were observed during the B-cell
depletion period 19, and in a French cohort of 17 patients, the
majority of relapses were observed after the reappearance of
CD19 cells 16. Data from the paediatric population also suggest
that maintaining prolonged B-cell depletion with repeated RTX
infusions reduces relapse frequency 30,31. However, relapses
are not always associated with B-cell recovery. In a paediatric
cohort of 17 patients, a high proportion remained relapse-free
despite B-cell recovery 32. This variability might be explained
by the heterogeneity of B-cell subpopulations that reconstitute
after RTX. A recent study by Colucci et al. found that in a pop-
ulation of 28 paediatric patients, following a single infusion of
RTX, transitional B cells, thought to have a more regulatory
role 33, appear ﬁrst in the circulation compared with memory
B cells. However, it was the reconstitution of isotype-switched
memory B cells thatwas a strong predictor of relapse suggesting
that monitoring of this B-cell population might be a useful tool
to identify those patients who are at high risk of relapse and
who might beneﬁt from re-treatment 34.
The question of whether long-term maintenance RTX ther-
apy is beneﬁcial or not has so far not been addressed by previ-
ous studies in the adult population. Takei et al. showed that
patients re-treated with RTX 6months after the ﬁrst infusion,
remained in remission for another 6months 19, the end of the
study’s observation period. We attempted to address this ques-
tion by re-treating patients 12months after their last RTX infu-
sion (T18), irrespective of CD19 counts. Four patients were
treated with this protocol: two relapsed 7months following
the additional RTX dose and the remaining two continued to
be in steroid-free remission until the end of the study period,
31 and 37months, respectively. Although the patient numbers
are small, these results, together with the observation thatmost
relapses occurred upon CD19 cell recovery, suggest that main-
tenance RTX therapy, keeping B cells below 100 cells/μl, may
have a beneﬁcial effect, but further studies comparing different
strategies are needed.
An important consideration with repeated RTX infusions is the
long-term safety as well as the development of human anti-
chimeric antibodies directed against RTX. We did not observe
any serious infections or persistent hypogammaglobulinaemia in
this group. Similar to previous reports, 46% of patients experi-
enced type I hypersensitivity reactions at the time of RTX infusion
24. However, data from the paediatric population suggest that
prolonged B-cell depletion may be complicated by opportunistic
infections such as Pneumocystis jiroveci pneumonia (PCP), and
therefore, PCP prophylaxis might be beneﬁcial 30. Development
of anti-chimeric antibodies has been recently reported in paediat-
ric patients receiving RTX for NS 35. Data from adult patients with
rheumatoid arthritis treated with repeated courses of RTX (up to
5) show that 9.2% developed antibodies but did not exhibit
decreased efﬁcacy or any additional safety issues 36. Newer, fully
humanized B-cell depleting agents such as ofatumumab and
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obinutuzumab might be a better long-term treatment option in
this population as they provide prolonged B-cell depletion with
a single dose, and there is less risk of de novo antibody formation.
In summary, our study shows that RTX is an effective
method of maintaining a steroid-free remission in frequently
relapsing or steroid-dependentMCD. The beneﬁt of a safe, long
lasting, single agent, in a population of young adults often hav-
ing problems with non-compliance and medication burden
from the multiple IS agents needed to control the disease and
the side effects experienced, make RTX a very attractive treat-
ment alternative to current strategies. Further studies are now
required to address speciﬁc questions including its role in
remission–induction and the beneﬁt of pre-emptive treatment
based on B-cell reconstitution.
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